These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 35351095)

  • 1. Glycemic outcomes of Advanced Hybrid Closed Loop system in children and adolescents with Type 1 Diabetes, previously treated with Multiple Daily Injections (MiniMed 780G system in T1D individuals, previously treated with MDI).
    Petrovski G; Al Khalaf F; Campbell J; Day E; Almajaly D; Hussain K; Pasha M; Umer F; Hamdan M; Khalifa A
    BMC Endocr Disord; 2022 Mar; 22(1):80. PubMed ID: 35351095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Glycemic Outcomes During the MiniMed
    Pihoker C; Shulman DI; Forlenza GP; Kaiserman KB; Sherr JL; Thrasher JR; Buckingham BA; Kipnes MS; Bode BW; Carlson AL; Lee SW; Latif K; Liljenquist DR; Slover RH; Dai Z; Niu F; Shin J; Jonkers RAM; Roy A; Grosman B; Vella M; Cordero TL; McVean J; Rhinehart AS; Vigersky RA;
    Diabetes Technol Ther; 2023 Nov; 25(11):755-764. PubMed ID: 37782145
    [No Abstract]   [Full Text] [Related]  

  • 3. The psychosocial outcomes of advanced hybrid closed-loop system in children and adolescents with type 1 diabetes.
    Jalilova A; Pilan BŞ; Demir G; Özbaran B; Balkı HG; Arslan E; Köse SG; Özen S; Darcan Ş; Gökşen D
    Eur J Pediatr; 2024 Jul; 183(7):3095-3103. PubMed ID: 38661816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advanced Hybrid Closed Loop in Adult Population With Type 1 Diabetes: A Substudy From the ADAPT Randomized Controlled Trial in Users of Real-Time Continuous Glucose Monitoring.
    van den Heuvel T; Kolassa R; Keuthage W; Kroeger J; Ré R; de Portu S; Vorrink L; Shin J; Castañeda J; Vigersky R; Cohen O
    J Diabetes Sci Technol; 2024 Sep; 18(5):1132-1138. PubMed ID: 36949671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomised controlled trial of Advanced Hybrid Closed Loop in an Adult Population with Type 1 Diabetes (ADAPT): study protocol and rationale.
    de Portu S; Vorrink L; Re R; Shin J; Castaneda J; Habteab A; Cohen O
    BMJ Open; 2022 Feb; 12(2):e050635. PubMed ID: 35110310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved Glycemic Outcomes With Medtronic MiniMed Advanced Hybrid Closed-Loop Delivery: Results From a Randomized Crossover Trial Comparing Automated Insulin Delivery With Predictive Low Glucose Suspend in People With Type 1 Diabetes.
    Collyns OJ; Meier RA; Betts ZL; Chan DSH; Frampton C; Frewen CM; Hewapathirana NM; Jones SD; Roy A; Grosman B; Kurtz N; Shin J; Vigersky RA; Wheeler BJ; de Bock MI
    Diabetes Care; 2021 Apr; 44(4):969-975. PubMed ID: 33579715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing advanced hybrid closed loop therapy and standard insulin therapy in pregnant women with type 1 diabetes (CRISTAL): a parallel-group, open-label, randomised controlled trial.
    Benhalima K; Beunen K; Van Wilder N; Ballaux D; Vanhaverbeke G; Taes Y; Aers XP; Nobels F; Marlier J; Lee D; Cuypers J; Preumont V; Siegelaar SE; Painter RC; Laenen A; Gillard P; Mathieu C
    Lancet Diabetes Endocrinol; 2024 Jun; 12(6):390-403. PubMed ID: 38697182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Body mass index, basal insulin and glycemic control in children with type 1 diabetes treated with the advanced hybrid closed loop system remain stable - 1-year prospective, observational, two-center study.
    Seget S; Jarosz-Chobot P; Ochab A; Polanska J; Rusak E; Witoszek P; Chobot A
    Front Endocrinol (Lausanne); 2022; 13():1036808. PubMed ID: 36303875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid Improvement in Time in Range After the Implementation of an Advanced Hybrid Closed-Loop System in Adolescents and Adults with Type 1 Diabetes.
    Beato-Víbora PI; Gallego-Gamero F; Ambrojo-López A; Gil-Poch E; Martín-Romo I; Arroyo-Díez FJ
    Diabetes Technol Ther; 2021 Sep; 23(9):609-615. PubMed ID: 33784187
    [No Abstract]   [Full Text] [Related]  

  • 10. A European Cost-Utility Analysis of the MiniMed™ 780G Advanced Hybrid Closed-Loop System Versus Intermittently Scanned Continuous Glucose Monitoring with Multiple Daily Insulin Injections in People Living with Type 1 Diabetes.
    Jendle J; Buompensiere MI; Ozdemir Saltik AZ; de Portu S; Smith-Palmer J; Pollock RF; Cohen O
    Diabetes Technol Ther; 2023 Dec; 25(12):864-876. PubMed ID: 37801658
    [No Abstract]   [Full Text] [Related]  

  • 11. Transitioning of People With Type 1 Diabetes From Multiple Daily Injections and Self-Monitoring of Blood Glucose Directly to MiniMed 780G Advanced Hybrid Closed-Loop System: A Two-Center, Randomized, Controlled Study.
    Matejko B; Juza A; Kieć-Wilk B; Cyranka K; Krzyżowska S; Chen X; Cohen O; Da Silva J; Malecki MT; Klupa T
    Diabetes Care; 2022 Nov; 45(11):2628-2635. PubMed ID: 35972259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching to the Minimed™ 780G system achieves clinical targets for CGM in adults with type 1 diabetes regardless of previous insulin strategy and baseline glucose control.
    Lepore G; Rossini A; Bellante R; Corsi A; Scaranna C; Dodesini AR; Trevisan R
    Acta Diabetol; 2022 Oct; 59(10):1309-1315. PubMed ID: 35857108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One-year experience of hybrid closed-loop system in children and adolescents with type 1 diabetes previously treated with multiple daily injections: drivers to successful outcomes.
    Petrovski G; Al Khalaf F; Campbell J; Umer F; Almajaly D; Hamdan M; Hussain K
    Acta Diabetol; 2021 Feb; 58(2):207-213. PubMed ID: 33044604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching to an advanced hybrid closed-loop system in real-world practice improves hypoglycemia awareness and metabolic control in adults with type 1 diabetes, particularly in those with impaired perception of hypoglycemia symptoms.
    Nattero-Chávez L; Lecumberri Pascual E; De La Calle E; Bayona Cebada A; Ruiz T; Quintero Tobar A; Lorenzo M; Sánchez C; Izquierdo A; Luque-Ramírez M; Escobar-Morreale HF
    Diabetes Res Clin Pract; 2023 May; 199():110627. PubMed ID: 36940793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. One-year follow-up comparison of two hybrid closed-loop systems in Italian children and adults with type 1 diabetes.
    Bassi M; Patti L; Silvestrini I; Strati MF; Ponzano M; Minuto N; Maggi D
    Front Endocrinol (Lausanne); 2023; 14():1099024. PubMed ID: 36777356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time In Tight Range in children and adolescents with type 1 diabetes: A cross-sectional observational single centre study evaluating efficacy of new advanced technologies.
    Schiaffini R; Lumaca A; Martino M; Rapini N; Deodati A; Amodeo ME; Ciampalini P; Matteoli MC; Pampanini V; Cianfarani S
    Diabetes Metab Res Rev; 2024 Jul; 40(5):e3826. PubMed ID: 38824455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness Analysis of an Advanced Hybrid Closed-Loop Insulin Delivery System in People with Type 1 Diabetes in Greece.
    Lambadiari V; Ozdemir Saltik AZ; de Portu S; Buompensiere MI; Kountouri A; Korakas E; Sharland H; Cohen O
    Diabetes Technol Ther; 2022 May; 24(5):316-323. PubMed ID: 34962140
    [No Abstract]   [Full Text] [Related]  

  • 18. 12-Month Real-Life Efficacy of the MiniMed 780G Advanced Closed-Loop System in Patients Living with Type 1 Diabetes: A French Observational, Retrospective, Multicentric Study.
    Lablanche S; Delagenière J; Jalbert M; Sonnet E; Benichou M; Arnold N; Spiteri A; Le Berre JP; Renard E; Chevalier N; Borot S; Bonnemaison E; Coffin C; Teissier MP; Benhamou PY; Borel JC; Penfornis A; Joubert M; Kessler L
    Diabetes Technol Ther; 2024 Jun; 26(6):426-432. PubMed ID: 38236643
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparison of MiniMed 780G system performance in users aged younger and older than 15 years: Evidence from 12 870 real-world users.
    Arrieta A; Battelino T; Scaramuzza AE; Da Silva J; Castañeda J; Cordero TL; Shin J; Cohen O
    Diabetes Obes Metab; 2022 Jul; 24(7):1370-1379. PubMed ID: 35403792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of time in target glucose range in real-world users of the MiniMed 780G system.
    Castañeda J; Mathieu C; Aanstoot HJ; Arrieta A; Da Silva J; Shin J; Cohen O
    Diabetes Obes Metab; 2022 Nov; 24(11):2212-2221. PubMed ID: 35791621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.